Novavax, Inc. (NASDAQ:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced the appointment of Bob Darius, Senior Vice President, Quality Operations. He will be responsible for leading the global Quality Operations of the company, including both Quality Assurance and Quality Control, as well as serving as a member of the company’s senior management team.

Mr. Darius joins Novavax with over 25 years of experience in Quality Assurance, Quality Control and strategic manufacturing. As VP Quality Operations at GlaxoSmithKline (GSK) Biologicals, he provided oversight of the North American and German Vaccine Manufacturing Operations for over 10 years and most recently transitioned to Head Quality Advocacy Liaison. Mr. Darius also held positions of increasing responsibility at the Food and Drug Administration, Center for Biologics Evaluation and Research, where he was a Senior Reviewer and Inspector, Advisor to the Deputy Center Director, Medicine, on counter-bioterrorism products. He earned a Bachelor of Science degree in Biology from George Mason University and completed graduate work in biotechnology at Johns Hopkins University.

“I am delighted to welcome Bob to the Novavax team,” said Stanley C. Erck, President and CEO. “At this critical stage of our development, during which we are implementing our commercialization plans for our RSV F Vaccine, Bob’s depth of experience and understanding of evolving regulatory and quality requirements will be critical to our success.” (Original Source)

Shares of Novavax closed yesterday at $4.87, down $0.12 or -2.40%. NVAX has a 1-year high of $15.01 and a 1-year low of $4.08. The stock’s 50-day moving average is $4.85 and its 200-day moving average is $7.16.

On the ratings front, Novavax has been the subject of a number of recent research reports. In a report issued on March 1, FBR analyst Vernon Bernardino reiterated a Buy rating on NVAX, with a price target of $17, which represents a potential upside of 249.1% from where the stock is currently trading. Separately, on February 29, Wedbush’s Heather Behanna reiterated a Buy rating on the stock and has a price target of $14.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Vernon Bernardino and Heather Behanna have a total average return of -29.7% and 1.4% respectively. Bernardino has a success rate of 17.6% and is ranked #3724 out of 3735 analysts, while Behanna has a success rate of 29.6% and is ranked #1697.

Novavax Inc is a clinical-stage vaccine company engaged in the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants.